![X-376 - ALK and MET 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第1頁](http://file4.renrendoc.com/view/351cfeae445e922c25ccf80af72b50a7/351cfeae445e922c25ccf80af72b50a71.gif)
![X-376 - ALK and MET 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第2頁](http://file4.renrendoc.com/view/351cfeae445e922c25ccf80af72b50a7/351cfeae445e922c25ccf80af72b50a72.gif)
![X-376 - ALK and MET 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第3頁](http://file4.renrendoc.com/view/351cfeae445e922c25ccf80af72b50a7/351cfeae445e922c25ccf80af72b50a73.gif)
![X-376 - ALK and MET 抑制劑 - 生命科學(xué)試劑 - MedChemExpress_第4頁](http://file4.renrendoc.com/view/351cfeae445e922c25ccf80af72b50a7/351cfeae445e922c25ccf80af72b50a74.gif)
下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEX-376Cat. No.: HY-16590CAS No.: 1365267-27-1分式: CHClFNO分量: 547.41作靶點(diǎn): ALK; c-Met/HGFR作通路: Protein Tyrosine Kinase/RTK儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 37 mg/mL (67.59 mM)* mea
2、ns soluble, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 1.8268 mL 9.1339 mL 18.2678 mL5 mM 0.3654 mL 1.8268 mL 3.6536 mL10 mM 0.1827 mL 0.9134 mL 1.8268 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 X-376種有效的雙重 的 ALK/MET 抑制劑,IC50 分別為 0.61 nM 和 0.6
3、9 nM。IC50 & Target ALK MET0.61 nM (IC50) 0.69 nM (IC50)體外研究The ability of X-376 to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEis tested. X-376 is potent in H3122 lung cancer cells harboring EML4-ALK E13;A
4、20 (IC50: 77 nM). X-376 isalso potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC50: 57 nM). Furthermore, X-376is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC50: 32 nM). X-376 also inhibits SY5Yneuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harbor
5、ing MET dependent,HepG2 cells and PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC50s of 142 nM, 150 nM,15.137 M and 3.062 M, respectively 1.體內(nèi)研究 The effects of X-376 in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that X-376 shows substantial bioavailabi
6、lity and moderate half-lives in vivo. Nude mice harboring H3122 xenograftsare treated with X-376 at 50 mg/kg bid. X-376 significantly delays the growth of tumors compared to vehiclealone. In the xenograft experiments, X-376 appears well-tolerated in vivo. Mouse weight is unaffected by X-376 treatmen
7、t. Drug-treated mice appear healthy and do not display any signs of compound related toxicity.To further assess potential side effects of X-376, additional systemic toxicity and toxico-kinetic studies areperformed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of X-37
8、6 at 25,50, 100 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels aredetermined to be 50 mg/kg for X-376. At NST levels, X-376 achieves an AUC of 41 Mhr and a Cmax of5.04 M 1.PROTOCOLCell Assay 1 For viability experiments, cells are seeded in 96-wel
9、l plates at 25%-33% confluency and exposed to drugs.The human lung adenocarcinoma cell lines H3122 and H2228 are treated with X-376 (10, 30, 100, 300 and1000 nM). SUDHL-1 lymphoma cells are treated with X-376 (5, 10, 30, 100 and 300 nM). SY5Yneuroblastoma cells are treated with X-376 (30, 100, 300 a
10、nd 1000 nM). At 72 hours post X-376 addition,Cell Titer Blue Reagent is added and fluorescence is measured on a Spectramax spectrophotometer. Allexperimental points are set up in hextuplicate replicates and are performed at least two independent times.IC50s are calculated using GraphPad Prism versio
11、n 5 for Windows. The curves are fit using a nonlinearregression model with a log (inhibitor) vs. response formula 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.Animal Mice 1Administration 1 Nude mice (nu/nu) are injected with H3122 cells. Once tumor
12、s reach an average volume of 450 mm3, a totalof 27 athymic mice harboring H3122 tumors are randomized and dosed via oral gavage with 50 mg/kg X-376or the control vehicle. Two, five, and fifteen hours after the single treatment (3 tumors/timepoint/group), miceare sacrificed and serum is collected for
13、 assessment of drug concentration using an LC-MS basedbioanalytical method.MCE has not independently confirmed the accuracy of these methods. They are for reference only.REFERENCES1. Lovly CM, et al. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinaseinhibitors. Cancer Res.2011 Jul 15;71(14):4920-31.McePdfHeight2/2 Master of Small Molecules 您邊的抑制劑師ww
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 電商平臺數(shù)據(jù)挖掘與市場分析方法
- 醫(yī)院打包采購合同范例
- 醫(yī)院助聽器租用合同范例
- 公司收購合同范例 工商
- 勞務(wù)員工轉(zhuǎn)讓合同范本
- 中國金剛石多層銑刀項(xiàng)目投資可行性研究報(bào)告
- 中國條碼設(shè)備行業(yè)市場發(fā)展監(jiān)測及投資前景展望報(bào)告
- 2021-2026年中國空氣壓縮機(jī)行業(yè)發(fā)展監(jiān)測及投資戰(zhàn)略規(guī)劃研究報(bào)告
- 現(xiàn)代服務(wù)業(yè)的創(chuàng)新路徑與市場發(fā)展趨勢研究
- 代工工廠保密合同范本
- 2024年01月江西2024年江西銀行贛州分行招考筆試歷年參考題庫附帶答案詳解
- 初三數(shù)學(xué)一元二次方程應(yīng)用題附答案
- 教職工安全管理培訓(xùn)
- 云南省曲靖市羅平縣2024-2025學(xué)年高二上學(xué)期期末地理試題( 含答案)
- 中國糖尿病防治指南(2024版)要點(diǎn)解讀
- 九宮數(shù)獨(dú)200題(附答案全)
- 燃?xì)膺^戶協(xié)議書
- 2024年南京信息職業(yè)技術(shù)學(xué)院高職單招(英語/數(shù)學(xué)/語文)筆試歷年參考題庫含答案解析
- 萬用表校準(zhǔn)報(bào)告
- 駱駝祥子1一24章批注
- 單位數(shù)字證書業(yè)務(wù)申請表
評論
0/150
提交評論